scholarly journals Preparation and Characterization of Flurbiprofen/β-Cyclodextrin Inclusion Complex

Author(s):  
Nguyen Thi Thanh Binh ◽  
Ho Thi Quynh Xuan ◽  
Nguyen Thi Hai Yen

This study aims to ameliorate the water solubility of flurbiprofen by using β-cyclodextrin (β-CD). The drug/ligand 1:1 (M/M) stoichiometry was determined based on the effect of β-CD on the solubility of flurbiprofen. Several methods of preparing flurbiprofen/β-CD inclusion complex were investigated and a solvent method using hot water to dissolve the starting materials was selected. The selected method showed a lot of advantages such as high complexing ability, good product yield, simple and eco-friendly process. The obtained product was characterized using various analytical techniques such as high-performance liquid chromatography, differential scanning calorimetry, Fourier transform infrared spectroscopy, X-ray diffraction and scanning electron microscopy. The product had a predominantly amorphous form with clathrate particles of about 2-7 µm in size, irregular edges and rough surfaces. The study results show that in the complexing process, flurbiprofen replaced water molecules located in the conical cavity of β-CD. The complex contained 19.91% flurbiprofen by mass with water solubility at 37°C was 1,100 µg/ml. The results also show that the complexing with β-CD significantly improved the water solubility of flurbiprofen by both speed and level. Keywords Flurbiprofen, β-cyclodextrin, inclusion complex, water solubility, preparation, characterization. References [1] K. Maroof, F. Zafar, H. Ali, S. Naveed, Flurbiprofen: a potent pain reliever, J. Bioequiv. Availab. 7(1) (2015) 056-058. https://doi.org/10.4172/jbb.1000214.[2] J.J. Thebault, G. Lagrue, C.E. Blatrix, L. Cheynier, R. Cluzan, Clinical pharmacology of flurbiprofen: a novel inhibitor of platelet aggregation, Curr. Med. Res. Opin. 5(1) (1977) 130-134. https://doi.org/10.1185/03007997709108990.[3] H. Geerts, Drug evaluation: (R)-flurbiprofen - an enantiomer of flurbiprofen for the treatment of Alzheimer's disease, Idrugs. 10(2) (2007) 121-133.[4] P.L. McGeer, M. Schulzer, E.G. McGeer, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies, Neurology. 47(2) (1996) 425-432. https://doi.org/10.1212/WNL.47.2.425.[5] S. Meister, I. Zlatev, J. Stab, D. Docter, S. Baches, et al., Nanoparticulate flurbiprofen reduces amyloid-β 42 generation in an in vitro blood-brain barrier model, Alzheimers Res. Ther. 5(6) (2013) 51-63. https://doi.org/10.1186/alzrt225.[6] K.P. Townsend, D. Praticò, Novel therapeutic opportunities for Alzheimer’s disease: focus on nonsteroidal anti-inflammatory drugs, FASEB J. 19(12) (2005) 1592-1601. https://doi.org/10.1096/fj.04-3620rev.[7] C.K. Kim, Y.S. Yoon, J.Y. Kong, Preparation and evaluation of flurbiprofen dry elixir as a novel dosage form using a spray-drying technique, Int. J. Pharm. 120 (1995) 21-31. https://doi.org/10.1016/0378-5173(94)00375-F.[8] M.J. Habib, M.T. Phan, G. Owusu-Ababio, Dissolution profiles of flurbiprofen in phospholipid solid dispersions, Drug Dev. Ind. Pharm. 24 (1998) 1077-1082. https://doi.org/10.3109/03639049809089952.[9] D.H. Oh, Y.J. Park, J.H. Kang, C.S. Yong, H.G. Choi, Physicochemical characterization and in vivo evaluation of flurbiprofen-loaded solid dispersion without crystalline change, Drug. Deliv. 18 (2010) 46-53. https://doi.org/10.3109/10717544.2010.509365.[10] G.D. Gupta, S. Jain, N.K. Jain, Formulation of an aqueous injection of flurbiprofen, Pharmazie. 52 (1997) 709-712. https://doi.org/10.1080/10826079708005547.[11] K.W. Ambade, S.L. Jadhav, M.N. Gambhire, S.D. Kurmi, V.J. Kadam, K.R. Jadhav, Formulation and evaluation of flurbiprofen microemulsion, Curr. Drug Deliv. 5 (2008) 32–41[12] H.H. Baek, S.Y. Kwon, S.J. Rho, W.S. Lee, H.J. Yang, J.M. Hah, H.G. Choi, Y.R. Kim, C.S. Yong, Enhanced solubility and bioavailability of flurbiprofen by cycloamylose, Arch. Pharm. Res. 34 (2011) 391-397. https://doi.org/10.1007/s12272-011-0306-x.[13] A. Muraoka, T. Tokumura, Y. Machida, Evaluation of the bioavailability of flurbiprofen and its β-cyclodextrin inclusion complex in four different doses upon oral administration to rats, Eur. J. Pharm. Biopharm. 58(3) (2004) 667-671. https://doi.org/10.1016/j.ejpb.2004.03.030.[14] T. Tokumura, A. Muraoka, Y. Machida, Improvement of oral bioavailability of flurbiprofen from flurbiprofen/beta-cyclodextrin inclusion complex by action of cinnarizine, Eur. J. Pharm. Biopharm. 73 (2009) 202-204. https://doi.org/10.1016/j.ejpb.2009.04.018.[15] D. Li, M. Han, P. Balakrishnan, Y. Yan, D. Oh, et al., Enhanced oral bioavailability of flurbiprofen by combined use of micelle solution and inclusion compound, Arch. Pharm. Res. 33(1) (2010) 95-101. https://doi.org/10.1007/s12272-010-2231-9.[16] H. Arima, K. Motoyama, T. Irie, Recent findings on safety profiles of cyclodextrins, cyclodextrin conjugates, and polypseudorotaxanes, in: E. Bilensoy (Ed.), Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and Future Industrial Applications, John Wiley & Sons Inc., Hoboken, 2011, pp. 91-122. https://doi.org/10.1002/9780470926819.ch5.[17] T.J. Grattan, Inclusion complexes of beta-cyclodextrin with flurbiprofen, ketoprofen and naproxen, International patent WO1995007104A1, March 16, 1995.[18] M. Cirri, C. Rangoni, F. Maestrelli, G. Corti, P. Mura, Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes, Drug Dev. Ind. Pharm. 31(7) (2005) 697-707. https://doi.org/10.1080/03639040500253694.[19] M. Tirunagari, N. Mehveen, M.F. Qureshi, J.P. Sultana, V. Tirunagari (2012), Solubility Enhancement of Flurbiprofen using Different Solubilization Techniques, Int. J. Pharm. Pharm. Sci. 4(4) (2012) 97-100.[20] P. Saokham, C. Muankaew, P. Jansook, T. Loftsson, Solubility of cyclodextrins and drug/cyclodextrin complexes, Molecules. 23(5) (2018) 1161-1175. https://doi.org/10.3390/molecules23051161.[21] S. Pereva, T. Sarafska, S. Bogdanova, T. Spassov, Efficiency of “cyclodextrin-ibuprofen” inclusion complex formation, J. Drug Deliv. Sci. Tec. 35 (2016) 34-39. https://doi.org/10.1016/j.jddst.2016.04.006.[22] T.T.B. Nguyen, N.A. Dang, M.A. Tran, T.H. Nguyen, Validation of a high-performance liquid chromatographic method with diod array detection for the quantification of flurbiprofen in 100 mg film-coated tablet, VNU Journal of Science: Medical and Pharmaceutical Sciences. 33(2) (2017) 41-49. https://doi.org/10.25073/2588-1132/vnumps.4085.[23] T. Higuchi, K.A. Connors, Phase-solubility techniques, Adv. Anal. Chem. Instrum. 4 (1965) 117-122.    

RSC Advances ◽  
2019 ◽  
Vol 9 (45) ◽  
pp. 26109-26115 ◽  
Author(s):  
Shuang Gao ◽  
Chao Bie ◽  
Qiuyu Ji ◽  
Haiyang Ling ◽  
Chunyan Li ◽  
...  

Cyanazine/HPβCD inclusion complex was prepared to improve water solubility and thermal stability and herbicidal activity of cyanazine.


2017 ◽  
Vol 12 (1) ◽  
pp. 155892501701200 ◽  
Author(s):  
Ahmet C. Turan ◽  
İlhan Özen ◽  
Hüsnü K. Gürakın ◽  
Enrico Fatarella

Imidacloprid-β-cyclodextrin (IMI-β-CD) inclusion complex was synthesized and effectively incorporated into filament yarns of polypropylene. The physical and thermal properties of IMI-β-CD inclusion complex were determined by Fourier transform infrared spectroscopy, thermogravimetric analysis, and differential scanning calorimetry. According to the results, formation of the inclusion complex was achieved along with enhanced thermal stability. The release profile of imidacloprid was monitored by high-performance chromatography measurements. Dissolution time of the IMI-β-CD inclusion complex was increased to 5 times that of the neat imidacloprid (from 9 h to 48 h). Poylpropylene filament yarns containing 3 wt.% IMI-β-CD inclusion complex released 84 wt.% of IMI within 21 days.


Sign in / Sign up

Export Citation Format

Share Document